BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28765159)

  • 1. The power of the few.
    Chen R; Pan Y; Gutmann DH
    Genes Dev; 2017 Jun; 31(12):1177-1179. PubMed ID: 28765159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. F25P preproinsulin abrogates the secretion of pro-growth factors from EGFRvIII cells and suppresses tumor growth in an EGFRvIII/wt heterogenic model.
    Wei JW; Cui JQ; Zhou X; Fang C; Tan YL; Chen LY; Yang C; Liu M; Kang CS
    Cancer Lett; 2016 Sep; 380(1):1-9. PubMed ID: 27317648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The EGFRvIII variant in glioblastoma multiforme.
    Gan HK; Kaye AH; Luwor RB
    J Clin Neurosci; 2009 Jun; 16(6):748-54. PubMed ID: 19324552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
    Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
    Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
    [No Abstract]   [Full Text] [Related]  

  • 6. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
    Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.
    Chistiakov DA; Chekhonin IV; Chekhonin VP
    Eur J Pharmacol; 2017 Sep; 810():70-82. PubMed ID: 28583430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis.
    Chen JR; Xu HZ; Yao Y; Qin ZY
    Acta Neurol Scand; 2015 Nov; 132(5):310-22. PubMed ID: 25846813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecularly targeted therapies for recurrent glioblastoma: current and future targets.
    Lau D; Magill ST; Aghi MK
    Neurosurg Focus; 2014 Dec; 37(6):E15. PubMed ID: 25434384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.
    An Z; Aksoy O; Zheng T; Fan QW; Weiss WA
    Oncogene; 2018 Mar; 37(12):1561-1575. PubMed ID: 29321659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between epidermal growth factor receptor amplification and ADP-ribosylation factor 1 methylation in human glioblastoma.
    López-Ginés C; Navarro L; Muñoz-Hidalgo L; Buso E; Morales JM; Gil-Benso R; Gregori-Romero M; Megías J; Roldán P; Segura-Sabater R; Almerich-Silla JM; Monleón D; Cerdá-Nicolás M
    Cell Oncol (Dordr); 2017 Aug; 40(4):389-399. PubMed ID: 28631186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
    Eskilsson E; Rosland GV; Talasila KM; Knappskog S; Keunen O; Sottoriva A; Foerster S; Solecki G; Taxt T; Jirik R; Fritah S; Harter PN; Välk K; Al Hossain J; Joseph JV; Jahedi R; Saed HS; Piccirillo SG; Spiteri I; Leiss L; Euskirchen P; Graziani G; Daubon T; Lund-Johansen M; Enger PØ; Winkler F; Ritter CA; Niclou SP; Watts C; Bjerkvig R; Miletic H
    Neuro Oncol; 2016 Dec; 18(12):1644-1655. PubMed ID: 27286795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment.
    Keller S; Schmidt MHH
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA.
    Halatsch ME; Schmidt U; Bötefür IC; Holland JF; Ohnuma T
    J Neurosurg; 2000 Feb; 92(2):297-305. PubMed ID: 10659018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor: a re-emerging target in glioblastoma.
    Hegi ME; Rajakannu P; Weller M
    Curr Opin Neurol; 2012 Dec; 25(6):774-9. PubMed ID: 23007009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteration of major vault protein in human glioblastoma and its relation with EGFR and PTEN status.
    Navarro L; Gil-Benso R; Megías J; Muñoz-Hidalgo L; San-Miguel T; Callaghan RC; González-Darder JM; López-Ginés C; Cerdá-Nicolás MJ
    Neuroscience; 2015 Jun; 297():243-51. PubMed ID: 25869624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.
    Nagane M; Narita Y; Mishima K; Levitzki A; Burgess AW; Cavenee WK; Huang HJ
    J Neurosurg; 2001 Sep; 95(3):472-9. PubMed ID: 11565870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFRvIII--a stable target for anti-EGFRvIII therapy.
    Banaszczyk M; Stoczynska-Fidelus E; Winiecka-Klimek M; Bienkowski M; Och W; Rieske P; Piaskowski S
    Anticancer Res; 2013 Dec; 33(12):5343-8. PubMed ID: 24324068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathologic diagnosis of epidermal growth factor receptor.
    Maire CL; Ligon KL
    Neuro Oncol; 2014 Oct; 16 Suppl 8(Suppl 8):viii1-6. PubMed ID: 25342599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy.
    Weller M; Kaulich K; Hentschel B; Felsberg J; Gramatzki D; Pietsch T; Simon M; Westphal M; Schackert G; Tonn JC; von Deimling A; Davis T; Weiss WA; Loeffler M; Reifenberger G;
    Int J Cancer; 2014 May; 134(10):2437-47. PubMed ID: 24614983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.